Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial
Tao Ge, Hongyi Zhang, Xinsheng Zhu, Meixin Teng, Yifei Zhou, Suyu Wang, Dongliang Bian, Lele Zhang, Haiyang Hu, Qiji Guo, Jincheng Su, Shiqi Hu, Huansha Yu, Yirui Zhou, Jie Huang, Jie Yang, Yuming Zhu, Yi Bao, Minwei Bao, Xuefei Hu, Wenxin He, Peng Zhang · 2025
Read Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial by Tao Ge, Hongyi Zhang, Xinsheng Zhu, Meixin Teng, Yifei Zhou, Suyu Wang, Dongliang Bian, Lele Zhang, Haiyang Hu, Qiji Guo, Jincheng Su, Shiqi Hu, Huansha Yu, Yirui Zhou, Jie Huang, Jie Yang, Yuming Zhu, Yi Bao, Minwei Bao, Xuefei Hu, Wenxin He, Peng Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12752746.txt.
Description
Tao Ge and co-authors ran, in a 2025 trial report, a phase 2 test of immune therapy before surgery for stage III lung cancer. About a third of lung cancer patients could in principle have their tumor removed. The LungMate-009 trial asked whether the drug sintilimab, given first, shrinks tumors safely enough to help surgery.
One hundred patients joined. Those whose tumors showed high PD-L1 got the drug alone for four cycles. Others got it with platinum chemotherapy. A team reviewed progress every two cycles, and surgery followed within about a month of the last dose. The main gauge was how much tumor died in the removed tissue. Tumor samples taken before and after were also sequenced. The design hunts for markers that predict who benefits most.
Catalog record
| CREATOR | Tao Ge, Hongyi Zhang, Xinsheng Zhu, Meixin Teng, Yifei Zhou, Suyu Wang, Dongliang Bian, Lele Zhang, Haiyang Hu, Qiji Guo, Jincheng Su, Shiqi Hu, Huansha Yu, Yirui Zhou, Jie Huang, Jie Yang, Yuming Zhu, Yi Bao, Minwei Bao, Xuefei Hu, Wenxin He, Peng Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |